Test-retest Evaluation of [18F]F-AraG PET
A phase 2 trial of [18F]F-ARAG PET in non-small-cell lung cancer, run by CellSight Technologies, Inc., now recruiting.
Overview
Test-retest Evaluation of [18F]F-AraG PET is a phase 2 interventional study registered as NCT06084806 by CellSight Technologies, Inc., with 10 participants planned, started 2023-10-31 and due to reach its primary completion in 2025-10-31. Interventions recorded: [18F]F-ARAG PET.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialOpen-Label Study of 18F-mFBG for Imaging Neuroblastoma
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialImaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Shares Fluorine-18 and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography) and the tag pipeline.
- TrialUsing 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Shares Fluorine-18 and the tag pipeline.
- Trial[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Fluorine-18 and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Fluorine-18 and the tag pipeline.